share_log

Vertex Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Vertex Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

福泰制药 | 10-Q：2024财年二季报
美股sec公告 ·  08/02 16:06
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals reported a 6% increase in net product revenues to $2.6 billion in Q2 2024 compared to $2.5 billion in Q2 2023, driven by the U.S. launch of TRIKAFTA for children and strong uptake in ex-U.S. markets. Total R&D and SG&A expenses rose to $1.3 billion in Q2 2024 from $1.0 billion in Q2 2023, largely due to the acquisition of Alpine Immune Sciences. The company's cash and equivalents decreased to $4.6 billion at the end of the period from $10.4 billion at the beginning, primarily due to the Alpine acquisition. Vertex continues to focus on cystic fibrosis (CF) treatments, with four approved medicines and a pipeline including programs in CF, sickle cell disease, beta thalassemia, and pain management. The company is preparing for near-term launches of new products in CF and acute pain. Vertex's future plans include advancing its diversified pipeline, with a focus on transformative medicines for serious diseases, and investing in research and development to balance the risks inherent in product development.
Vertex Pharmaceuticals reported a 6% increase in net product revenues to $2.6 billion in Q2 2024 compared to $2.5 billion in Q2 2023, driven by the U.S. launch of TRIKAFTA for children and strong uptake in ex-U.S. markets. Total R&D and SG&A expenses rose to $1.3 billion in Q2 2024 from $1.0 billion in Q2 2023, largely due to the acquisition of Alpine Immune Sciences. The company's cash and equivalents decreased to $4.6 billion at the end of the period from $10.4 billion at the beginning, primarily due to the Alpine acquisition. Vertex continues to focus on cystic fibrosis (CF) treatments, with four approved medicines and a pipeline including programs in CF, sickle cell disease, beta thalassemia, and pain management. The company is preparing for near-term launches of new products in CF and acute pain. Vertex's future plans include advancing its diversified pipeline, with a focus on transformative medicines for serious diseases, and investing in research and development to balance the risks inherent in product development.
福泰制药Q2 2024年净产品收入同比增长6%，达到26亿美元，而2023年Q2则为25亿美元，主要由于TRIKAFTA儿童用药在美国上市和海外市场表现强劲所带来的推动。研发和销售费用从2023年Q2的10亿美元增至2024年Q2的13亿美元，主要是由于对alpine immune的收购所致。该公司现金及现金等价物从期初的104亿美元下降至期末的46亿美元，主要是由于alpine收购。 Vertex继续专注于囊性纤维化（CF）治疗，并拥有四种获批药物以及包括CF、镰状细胞贫血、β地中海贫血和疼痛管理计划在内的一系列项目。该公司正在为CF和急性疼痛的新产品近期上市做准备。Vertex的未来计划包括推动其多样化的项目线，并将重点放在治疗严重疾病的革命性药品上，并投资于研究和开发，以平衡产品开发所固有的风险。
福泰制药Q2 2024年净产品收入同比增长6%，达到26亿美元，而2023年Q2则为25亿美元，主要由于TRIKAFTA儿童用药在美国上市和海外市场表现强劲所带来的推动。研发和销售费用从2023年Q2的10亿美元增至2024年Q2的13亿美元，主要是由于对alpine immune的收购所致。该公司现金及现金等价物从期初的104亿美元下降至期末的46亿美元，主要是由于alpine收购。 Vertex继续专注于囊性纤维化（CF）治疗，并拥有四种获批药物以及包括CF、镰状细胞贫血、β地中海贫血和疼痛管理计划在内的一系列项目。该公司正在为CF和急性疼痛的新产品近期上市做准备。Vertex的未来计划包括推动其多样化的项目线，并将重点放在治疗严重疾病的革命性药品上，并投资于研究和开发，以平衡产品开发所固有的风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息